Octagon Therapeutics

Octagon is developing targeted drugs for severe autoimmune diseases that spare healthy immune functioning.

Cambridge, MA, USA

One Liner

One Liner
Octagon is developing targeted drugs for severe autoimmune diseases that spare healthy immune functioning.

What Problem We are Solving

Current medicines for autoimmune diseases, including steroids and immunosuppressive drugs, indiscriminately suppress the immune system. This puts patients at risk of potentially deadly infection and most of these medicines cannot be used long-term. As result, patients with severe autoimmune disease are poorly controlled and go through periods of intense disease exacerbation (flare) per year. Clinicians have a limited set of medicines with which to treat these patients and most are repurposed from transplant medicine or oncology.

About Us

About Us
Octagon is developing targeted medicines that specifically inhibit disease-driving processes based on a novel disease pathway. The company has 3 assets in active development. These medicines have the potential to address severe autoimmune diseases including Lupus and Arthritis and rare diseases such as Pemphigus/Pemphigoid, Myasthenia, and Scleroderma. Octagon's most advanced drug candidate is a monoclonal antibody. These new medicines are the result of a differentiated drug discovery platform that directly makes use of human clinical samples to identify disease-driving biological pathways. This platform has formed the basis for a multi-year funded partnership with Novo Nordisk, a top-ten multinational pharmaceutical company.

Venture Highlights

Octagon has independently won 3 startup competitions sponsored by pharmaceutical companies. This includes Amgen  and Pfizer. This resulted in $165,000 in support.

The company executed a multi-year partnership with Novo Nordisk focused on inflammatory disease. Novo produced a professional quality video promotion highlighting the relationship.

Octagon is proud to count industry veterans, professional investors, and venture capital funds among our Seed investors. We have built an organization with a strong corporate culture and very low attrition, most team members have been with the company for 4 years or more.

Business Model

Business Model
Octagon is focused on building a multi-asset biotech company with a powerful discovery platform.  We will not independently commercialize our products, but will instead pursue licensing/M&A upon reaching early clinical validation. These deals can be very large in the autoimmune disease space, with significant upfront payments in the hundreds of millions and additional downstream milestone payments that can be even larger.  Octagon is a build-to-buy company, with an attractive technology and team that would be value creating for larger organizations.

Competitive Advantage

Octagon's medicines target a new pathway that drives the pathological activation of immune cells that causes autoimmune disorders. This biology is present in several high-value autoimmune diseases.  Blocking this pathway can restore immune homeostasis without inhibiting normal immune pathogen response, meaning that Octagon's medicines can be taken chronically to maintain long-term remission. This is a radically new way of thinking about treating autoimmune disease, enabled by new biological discoveries. The platform that led to the discovery of this pathway can be applied in other disease areas and has led to a partnership focused on fibrosis.


Revenue To Date
Revenue YTD
Burn Rate


Total Users
Total Users (Past 30 Days)
Daily Active Users
Monthly Active Users
Total Paying Users
MoM Growth Users
Organic Traffic %

Customer Costs


Go-To Market Strategy

Business Strategy
Octagon is focused on our strengths in drug discovery and research and development. Our strategy is to exit to a larger company prior to the full approval of our medicines. Larger pharmaceutical companies have established sales channels and massive marketing budgets. Building equivalent capabilities would be incredibly expensive and redundant. We will not be undertaking go-to-market or commercialization work independently.

Competitive Analysis

Competitive Analysys
Current therapies for autoimmune disease are focused on killing immune cells. Roche/Genentech sells an approved market-leading product called Rituxan that causes the death of most B cells. This product was originally developed for lymphoma but recently received approval for a rare autoimmune disease.
Caballeta Bio is developing an even more aggressive cell therapy for killing nearly all B cells. This medicine will be extremely expensive and presents risk to patients. This medicine is still in development.
Sanofi acquired a Btk inhibitor program from Principia that targets B cells in a new way. This program is still in clinical development and has shown weak effectiveness.
Unlike all of these approaches, Octagon's drugs will not kill immune cells, but will instead prevent the disease-driving activation of these cells based on the novel biology that Octagon has discovered.
Competitor Website
Sanofi www.sanofi.com
Cabelleta Bio www.cabalettabio.com
Roche www.roche.com


We are open to meeting up to grab a coffee, or just to chat. We would really enjoy your feedback and insight into our venture and would be happy to discuss anything that you are currently working on to see if we can be of service!



Name Amount
Amount Raise To Date $6.4M
Type of Raise Convertible Note

Seed Bridge
Grant Dollars Awarded



Business Stage

Business Stage

Business Type

Business Types
Investor-Backed, Venture Capital Backed




Last Updated: 12/16/22

Think a friend might be interested in this?

Enter their email to share it with them!

Thank you for the feedback!

We take all inquiries to heart and look forward to adding new features and finding out new ways to help.

We love feedback as much as you do.

We built this site for you.

Let us know how to make it better and what features you want going forward!